The purpose of this resource is to provide tissue, cells and pathology services to all 5 research projects and career or research development awardees covered by this application. The plan for this Lymphoma SPORE is to combine pathology resources of the Dan L Duncan Cancer Center at Baylor College of Medicine (BCM) and its affiliated institutions with those of The Methodist Hospital to ensure adequate numbers and timely delivery of tissue/cell samples for the projected needs of project investigators. It will therefore co-ordinate acquisition of tissue for banking from lymphoma and CLL patients at 5 affiliated hospitals in the Texas Medical Center, by relying on tissue collection and distribution systems already in place. The capacity to obtain samples from 5 affiliated hospitals will greatly increase the number of specimens we are able to analyze, store and distribute. The core will also provide pathology services including routine tissue preparation, immunohistochemical staining, laser capture microdissection, preparation of tissue microarrays, flow cytometry, detection of minimal residual disease and in situ hybridization for viral RNAs. These tasks are essential to the successful completion of planned experiments in each project and will be performed by expert pathologists and histotechnologists with substantial experience in providing core services to SPORE investigators. We believe the resultant Tissue Core will have the necessary laboratory space, equipment and human resources to handle the workload outlined for the Lymphoma SPORE. This core also contains bioinformatics support to support tissue-banking software needs for the lymphoma core and includes investigators with expertise in developing CDEs and experience working with the BCM Prostate SPOREs to develop a caBIG compliant system linking biospecimen data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA126752-05
Application #
8330919
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
5
Fiscal Year
2011
Total Cost
$308,924
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Ngai, Ho; Tian, Gengwen; Courtney, Amy N et al. (2018) IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol 201:2141-2153
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Nabekura, Tsukasa; Chen, Zhiying; Schroeder, Casey et al. (2018) Crk Adaptor Proteins Regulate NK Cell Expansion and Differentiation during Mouse Cytomegalovirus Infection. J Immunol 200:3420-3428
Shum, Thomas; Kruse, Robert L; Rooney, Cliona M (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther 18:653-664
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
McLaughlin, Lauren P; Rouce, Rayne; Gottschalk, Stephen et al. (2018) EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood 132:2351-2361

Showing the most recent 10 out of 270 publications